France’s competition authority ordered Engie on Monday to raise its natural gas prices for companies, saying that in some cases the energy company appeared to be selling gas at below cost and so harming competitors.
The antitrust body’s investigation followed a complaint by Engie competitor Direct Energie in October, which argued some of Engie’s market offers were anti-competitive.
“It has become clear that Engie’s price offers could in certain cases be qualified as predatory pricing and could push other players out of the market,” the authority said, adding it was also launching an investigation into Engie’s price practices for residential customers.
Since the opening of the French gas market in 2007, former monopoly Engie continues to sell gas to retail customers at regulated tariffs set by energy regulator CRE, but also sells gas at unregulated prices to retail and corporate customers in competition with new market entrants.
In June 2015, Engie had 79 percent of the residential French gas market and 63 percent of the non-residential market, according to an antitrust body document about the ruling.
The Autorite de la Concurrence antitrust body said that, according to CRE, part of the commercial costs of Engie’s unregulated gas prices for residential customers was subsidised by Engie’s gas sales at regulated prices.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Trump Administration Steps Up Pressure On EU Digital Laws
May 18, 2025 by
CPI
Elton John Slams UK Government’s AI Copyright Plan as ‘Theft’
May 18, 2025 by
CPI
Anthropic’s Legal Team Blames AI “Hallucination” for Citation Error in Copyright Lawsuit
May 18, 2025 by
CPI
Intel Challenges €376 Million EU Antitrust Fine in Ongoing Legal Battle
May 18, 2025 by
CPI
FTC Chairman Highlights Fiscal Responsibility and Consumer Protection in House Testimony
May 18, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas